IP Library Granted Patent US 12,059,191
Granted Patent B2
US 12,059,191 · App. 16/874,376 · Granted Aug 13, 2024

Terminating drying cycles by monitoring impedance in electrosurgical systems

Inventors: Kester Julian Batchelor (Mound, MN); Wayne Williams (Penarth, GB)
Assignee: Gyrus ACMI, Inc.
A61B18/1206A61B18/00A61B18/1233A61B18/14A61B18/1442A61B18/1445A61B2017/00017A61B2017/00115A61B2017/00132A61B2017/00154A61B2017/00194A61B2018/00589A61B2018/00595A61B2018/0063A61B2018/00642A61B2018/00648A61B2018/00654A61B2018/00666A61B2018/00678A61B2018/00684A61B2018/00702A61B2018/00708A61B2018/00714A61B2018/0072A61B2018/0075A61B2018/00755A61B2018/00761A61B2018/00767A61B2018/00779A61B2018/00791A61B2018/00827A61B2018/00875A61B2018/00886A61B2018/00898A61B2018/00928A61B2018/00994A61B2018/1455A61B2018/1467
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,059,191
App. No.
16/874,376
Granted
Aug 13, 2024
Kind
B2
Abstract

Apparatus and associated methods relate to controlling electrical power of an electrotherapeutic signal that is provided to a biological tissue engaged by an electrosurgical instrument during a medical procedure. Electrical power—a product of a voltage difference across and an electrical current conducted by the engaged biological tissue—is controlled according to a therapeutic schedule. The electrotherapeutic schedule can be reduced or terminated in response to a termination criterion being met. In some examples, the termination criterion is a current characteristic, such as, for example, a decrease in current conducted by the engaged biological tissue. In some examples, the termination criterion is a biological tissue resistance characteristic, such as, for example, an increase in the biological tissue resistance that exceeds a predetermined delta resistance value.

Claims (52)

1. A surgical generator configured to generate and provide controlled electrical power of a therapeutic signal to biological tissue in electrical communication with a surgical instrument, the surgical generator comprising:

a measurement circuit coupled to a control circuit and configured to measure a first impedance, a second impedance, and a third impedance of the biological tissue during a therapeutic phase; and

the control circuit in communication with an electrical-energy source, the electrical-energy source electrically coupled to the surgical instrument and configured to generate the therapeutic signal, the control circuit configured to:

store the first impedance measurement as a minimum impedance measurement;

store the second impedance measurement as the minimum impedance measurement when the second impedance measurement is less than the first impedance measurement;

control an energy delivery of the therapeutic signal provided to the biological tissue during a therapeutic phase; and

in response to the third impedance measurement changing by a predetermined delta impedance value, reduce but continue the energy delivery during the therapeutic phase, wherein the predetermined delta impedance is a change in impedance relative to the minimum impedance measurement during a pulse of the therapeutic signal.

2. The surgical generator of claim 1 , wherein the control circuit is configured to:

control an electrical power of the therapeutic signal provided to the biological tissue.

3. The surgical generator of claim 1 , wherein the control circuit is configured to:

control a voltage of the therapeutic signal provided to the biological tissue.

4. The surgical generator of claim 3 , wherein the control circuit is configured to:

monitor the voltage of the therapeutic signal; and

maintain the voltage when the voltage meets a voltage threshold.

5. The surgical generator of claim 1 , wherein the therapeutic phase is a drying phase.

6. The surgical generator of claim 5 , wherein the measurement circuit is configured to measure the first impedance conducted by the biological tissue and measure the third impedance conducted by the biological tissue during the drying phase, and wherein the control circuit is configured to:

control the electrical-energy source to provide a drying signal to the biological tissue during the drying phase; and

reduce the drying phase in response to a comparison between minimum impedance measurement and the third impedance measurement indicating a phase change of liquid in the biological tissue.

7. The surgical generator of claim 6 , wherein the control circuit is configured to control the drying signal according to a drying schedule.

8. A surgical generator configured to generate and provide controlled electrical power of a therapeutic signal to biological tissue in electrical communication with a surgical instrument, the surgical generator comprising:

a measurement circuit coupled to a control circuit and configured to measure a first impedance, a second impedance, and a third impedance of the biological tissue during a therapeutic phase; and

the control circuit in communication with an electrical-energy source, the electrical-energy source electrically coupled to the surgical instrument and configured to generate the therapeutic signal, the control circuit configured to:

store the first impedance measurement as a minimum impedance measurement;

store the second impedance measurement as the minimum impedance measurement when the second impedance measurement is less than the first impedance measurement;

control an energy delivery of the therapeutic signal provided to the biological tissue during a therapeutic phase; and

in response to the third impedance measurement changing by a predetermined delta impedance value, reduce but continue the energy delivery during the therapeutic phase, wherein the predetermined delta impedance is a change in impedance relative to the minimum impedance measurement taken at a set time interval after the therapeutic phase has begun.

9. The surgical generator of claim 8 , wherein the control circuit is configured to:

control an electrical power of the therapeutic signal provided to the biological tissue.

10. The surgical generator of claim 8 , wherein the control circuit is configured to:

control a voltage of the therapeutic signal provided to the biological tissue.

11. The surgical generator of claim 10 , wherein the control circuit is configured to:

monitor the voltage of the therapeutic signal; and

maintain the voltage when the voltage meets a voltage threshold.

12. The surgical generator of claim 8 , wherein the therapeutic phase is a drying phase.

13. The surgical generator of claim 12 , wherein the measurement circuit is configured to measure the first impedance conducted by the biological tissue and measure the third impedance conducted by the biological tissue during the drying phase, and wherein the control circuit is configured to:

control the electrical-energy source to provide a drying signal to the biological tissue during the drying phase; and

reduce the drying phase in response to a comparison between minimum impedance measurement and the third impedance measurement indicating a phase change of liquid in the biological tissue.

14. The surgical generator of claim 13 , wherein the control circuit is configured to control the drying signal according to a drying schedule.

15. A method of generating and providing controlled electrical power of a therapeutic signal to biological tissue in electrical communication with a surgical instrument, the method comprising:

measuring a first impedance, a second impedance, and a third impedance of the biological tissue during a therapeutic phase;

storing the first impedance measurement as a minimum impedance measurement;

storing the second impedance measurement as the minimum impedance measurement when the second impedance measurement is less than the first impedance measurement;

generating the therapeutic signal;

controlling an energy delivery of the therapeutic signal provided to the biological tissue during a therapeutic phase; and

in response to the third impedance measurement changing by a predetermined delta impedance value, reducing but continuing the energy delivery during the therapeutic phase, wherein the predetermined delta impedance is a change in impedance relative to the first impedance measurement during a pulse of the therapeutic signal.

16. The method of claim 15 , comprising:

controlling an electrical power of the therapeutic signal provided to the biological tissue.

17. The method of claim 15 , comprising:

controlling a voltage of the therapeutic signal provided to the biological tissue.

18. The method of claim 17 , comprising:

monitoring the voltage of the therapeutic signal; and

maintaining the voltage when the voltage meets a voltage threshold.

Assignments (3)
CONFIRMATORY ASSIGNMENT Recorded Dec 2, 2022
From: GYRUS MEDICAL LIMITED
To: GYRUS ACMI, INC. D/B/A OLYMPUS SURGICAL TECHNOLOGIES AMERICA
Reel/Frame 062048/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2022
From: BATCHELOR, KESTER JULIAN
To: GYRUS ACMI, INC. D/B/A OLYMPUS SURGICAL TECHNOLOGIES AMERICA
Reel/Frame 061122/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2022
From: WILLIAMS, WAYNE
To: GYRUS MEDICAL LIMITED
Reel/Frame 061123/0127 →
Continuity (8)
Continuation PCTUS2020031857 · May 7, 2020
Provisional Application 62905366 · Sep 24, 2019
Provisional Application 62905318 · Sep 24, 2019
Provisional Application 62905337 · Sep 24, 2019
Provisional Application 62905360 · Sep 24, 2019
Provisional Application 62905345 · Sep 24, 2019
Provisional Application 62845647 · May 9, 2019
Related Publication 20200352630A1 · Nov 12, 2020
Cited By (4)
US 12,193,721 US 12,303,183 US 12,440,262 US 12,714,489